International Web-based consultation on priorities for translational breast cancer research

被引:74
作者
Dowsett, Mitch [1 ]
Goldhirsch, Aron [2 ]
Hayes, Daniel F. [3 ]
Senn, Hans-Joerg [4 ]
Wood, William [5 ]
Viale, Giuseppe [6 ]
机构
[1] Royal Marsden Hosp, Acad Dept Biochem, London SW3 6JJ, England
[2] European Inst Oncol, Dept Med, Dept Med Oncol, Div Med Oncol, I-20141 Milan, Italy
[3] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA
[4] Treatment & Prevent ZeTuP, Ctr Tumour Detect, CH-9006 St Gallen, Switzerland
[5] Emory Univ Hosp, Dept Surg, Atlanta, GA 30322 USA
[6] European Inst Oncol, Dept Pathol, I-20141 Milan, Italy
关键词
D O I
10.1186/bcr1798
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Large numbers of translational breast cancer research topics have been completed or are underway, but they differ widely in their immediate and/or future importance to clinical management. We therefore conducted an international Web-based consultation of breast cancer professionals to identify the topics most widely considered to be of highest priority. Methods Potential participants were contacted via two large e-mail databases and asked to register, at a Web site, the issues that they felt to be of highest priority. Four hundred nine questions were reduced by a steering committee to 70 unique issues, and registrants were asked to select the 6 questions they considered to be the most important. Results Votes were recorded from 420 voters ( 2,520 votes) from 48 countries, with 48% of voters coming from North America. Half of the voters identified themselves as clinicians, with the remainder being academics, research scientists, or pathologists. The highest priority was to identify molecular signatures to select patients who could be spared chemotherapy, which gained about 50% more votes than the second topic and was consistently voted top by voters in North America, Europe, and the rest of the world. Research scientists voted the determination of the role of stem cells in breast cancer development, progression, and treatment sensitivity as the most important issue, but this was considered the sixth priority for clinicians and fourth overall. Conclusion This exercise may bring a greater focus of research resources onto issues voted as top priorities.
引用
收藏
页数:7
相关论文
共 7 条
[1]   Basal-like breast carcinomas: clinical outcome and response to chemotherapy [J].
Banerjee, S. ;
Reis-Filho, J. S. ;
Ashley, S. ;
Steele, D. ;
Ashworth, A. ;
Lakhani, S. R. ;
Smith, I. E. .
JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) :729-735
[2]   Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial [J].
Bogaerts, Jan ;
Cardoso, Fatima ;
Buyse, Marc ;
Braga, Sofia ;
Loi, Sherene ;
Harrison, Jillian A. ;
Bines, Jacques ;
Mook, Stella ;
Decker, Nuria ;
Ravdin, Peter ;
Therasse, Patrick ;
Rutgers, Emiel ;
van't Veer, Laura J. ;
Piccart, Martine .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10) :540-551
[3]   Systemic treatments for women with breast cancer: outcome with relation to screening for the disease [J].
Goldhirsch, A ;
Colleoni, M ;
Domenighetti, G ;
Gelber, RD .
ANNALS OF ONCOLOGY, 2003, 14 (08) :1212-1214
[4]   Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].
Sorlie, T ;
Perou, CM ;
Tibshirani, R ;
Aas, T ;
Geisler, S ;
Johnsen, H ;
Hastie, T ;
Eisen, MB ;
van de Rijn, M ;
Jeffrey, SS ;
Thorsen, T ;
Quist, H ;
Matese, JC ;
Brown, PO ;
Botstein, D ;
Lonning, PE ;
Borresen-Dale, AL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874
[5]   TAILORx: Trial assigning individualized options for treatment (Rx) [J].
Sparano, Joseph A. .
CLINICAL BREAST CANCER, 2006, 7 (04) :347-350
[6]  
*TOP 10, TOP 10 GLOB CONS
[7]   A gene-expression signature as a predictor of survival in breast cancer. [J].
van de Vijver, MJ ;
He, YD ;
van 't Veer, LJ ;
Dai, H ;
Hart, AAM ;
Voskuil, DW ;
Schreiber, GJ ;
Peterse, JL ;
Roberts, C ;
Marton, MJ ;
Parrish, M ;
Atsma, D ;
Witteveen, A ;
Glas, A ;
Delahaye, L ;
van der Velde, T ;
Bartelink, H ;
Rodenhuis, S ;
Rutgers, ET ;
Friend, SH ;
Bernards, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :1999-2009